The Role of MAO-B Inhibitors in the Treatment of Parkinson’s Disease

John Bertoni, Lawrence Elmer

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


Selegiline was first discovered in the 1960s and has been lauded as a virtual fountain of youth due to its potential neuroprotective effects,1 only to be later denigrated as a suspected cause of higher mortality in patients with Parkinson s disease (PD).2 While neither of these extreme viewpoints seems reasonable now, selegiline nevertheless still invokes lively discussion regarding its role as a ther apeutic agent for PD and a variety of other neuropsychiatric illnesses. In this section, we review the historical development of selegiline, its mechanism of action, shortand long-term clinical trials, and conclude with current recommendations for its use in the management of PD.

Original languageEnglish (US)
Title of host publicationParkinson's Disease
PublisherCRC Press
Number of pages14
ISBN (Electronic)9780203508596
ISBN (Print)9780849315909
StatePublished - Jan 1 2004
Externally publishedYes

ASJC Scopus subject areas

  • General Neuroscience
  • General Medicine


Dive into the research topics of 'The Role of MAO-B Inhibitors in the Treatment of Parkinson’s Disease'. Together they form a unique fingerprint.

Cite this